市場調查報告書

全球輕度創傷性腦損傷(MTBI)治療市場:成長,趨勢,及預測(2020年∼2025年)

Mild Traumatic Brain Injury Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921914
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
全球輕度創傷性腦損傷(MTBI)治療市場:成長,趨勢,及預測(2020年∼2025年) Mild Traumatic Brain Injury Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 112 Pages
簡介

全球輕度創傷性腦損傷(MTBI)治療市場在預測期間內預計將以3.8%的年複合成長率成長。促進該市場成長的主要原因,是輕度創傷性腦損傷的發生率增加,及持續性產品開發與核准等。

本報告提供全球輕度創傷性腦損傷(MTBI)治療市場的相關調查,市場機會和趨勢,成長及阻礙因素,各治療、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 輕度創傷性腦損傷的增加率
    • 持續性產品開發與核准
  • 市場阻礙因素
    • 嚴格的法律規範
    • 受訓練的專家不足
  • 波特的五力分析

第5章 市場區隔

  • 各治療
    • 藥物
    • 手術
  • 各終端用戶
    • 醫院
    • 診所
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Grace Laboratories LLC.
    • Integra LifeSciences Corporation
    • Medtronic PLC
    • Neuren Pharmaceuticals Ltd.
    • NeuroVive Pharmaceutical AB
    • Stemedica Cell Technologies Inc.
    • TEVA Pharmaceutical Industries Ltd.
    • Vasopharm GmbH

第7章 市場機會及今後趨勢

目錄
Product Code: 67117

Market Overview

Global Mild Traumatic Brain Injury Treatment market is expected to witness a CAGR of 3.8% during the forecast period. Certain factors that are driving the market growth include Increasing Incidence Of Mild Traumatic Brain Injuries, and Ongoing Product Development and Approval.

Mild traumatic brain injury (MTBI) is a frequent medical condition, and some patients report long-lasting problems after MTBI. In order to prevent MTBI, knowledge of epidemiology is an important and potential bias in studies should be explored. Traumatic brain injury (TBI) is a complex injury comprising a spectrum from mild TBI (MTBI) with low risk of persistent disability, to the most severe TBI with devastating brain damage. However, MTBI constitutes 80-90 % of all TBI.

Scope of the Report

A patient with mild traumatic brain injury is a person who has had a traumatically induced physiological disruption of brain function. It has been recognized that patients with a mild traumatic brain injury can exhibit persistent emotional, cognitive, behavioral, and physical symptoms, alone or in combination, which may produce a functional disability.

Key Market Trends

Hospital is Expected to Hold Significant Market Share in the End User Segment

Therapy for MTBI usually begins in the hospital and continues at an inpatient rehabilitation unit, a residential treatment facility or outpatient services. The type and duration of rehabilitation are different for everyone, depending on the severity of the brain injury and what part of the brain was injured. People with mild traumatic brain injuries may also have other injuries that need to be addressed. Additional treatments in the emergency room or intensive care unit of a hospital generally focus on minimizing secondary damage due to inflammation, bleeding or reduced oxygen supply to the brain.

North America Dominates the Market and Expected to do Same in the Forecast Period

Traumatic brain injury (TBI), also known as acquired brain injury, head injury, or brain injury, causes substantial disability and mortality in the American population. It occurs when a sudden trauma damages the brain and disrupts normal brain function. TBI often has profound physical, psychological, cognitive, emotional, and social effects on the lives of American people. Mild TBI appears to be vastly under-diagnosed in the setting of systemic trauma, even in trauma centers. According to the CDC, there were approximately 2.8 million TBI-related emergency department visits, hospitalizations, and deaths in the United States in 2015. Hence, the rising prevalence of MTBI is expected to drive the overall growth of the market across the entire region.

Competitive Landscape

The global Mild Traumatic Brain Injury Treatment market is highly competitive and consists of a number of major players. Companies like Grace Laboratories LLC., Integra LifeSciences Corporation, Medtronic PLC, Neuren Pharmaceuticals Ltd., NeuroVive Pharmaceutical AB , Stemedica Cell Technologies Inc., TEVA Pharmaceutical Industries Ltd., Vasopharm GmbH, among others, hold the substantial market share in the Mild Traumatic Brain Injury Treatment market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence Of Mild Traumatic Brain Injuries
    • 4.2.2 Ongoing Product Development And Approval
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Framework
    • 4.3.2 Shortage Of Trained Professionals
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Drugs
    • 5.1.2 Surgery
  • 5.2 End Users
    • 5.2.1 Hospitals
    • 5.2.2 Clinics
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Grace Laboratories LLC.
    • 6.1.2 Integra LifeSciences Corporation
    • 6.1.3 Medtronic PLC
    • 6.1.4 Neuren Pharmaceuticals Ltd.
    • 6.1.5 NeuroVive Pharmaceutical AB
    • 6.1.6 Stemedica Cell Technologies Inc.
    • 6.1.7 TEVA Pharmaceutical Industries Ltd.
    • 6.1.8 Vasopharm GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS